Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice

被引:0
|
作者
Nanni, P
Nicoletti, G
De Giovanni, C
Croci, S
Astolfi, A
Landuzzi, L
Di Carlo, E
Iezzi, M
Musiani, P
Lollini, PL
机构
[1] Univ Bologna, Canc Res Sect, Dept Expt Pathol, I-40126 Bologna, Italy
[2] Ist Ortoped Rizzoli, I-40136 Bologna, Italy
[3] Univ G DAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Rhabdomyosarcomas derive from the skeletal muscle lineage and harbor a variety of genetic and molecular lesions. However, it is not clear which molecular alterations have a pathogenetic role. We show that activation of the HER-2/neu oncogene coupled with inactivation of the oncosuppressor gene p53 causes rhabdomyosarcoma in mice. At the age of 11-21 weeks, all male mice carrying both genetic lesions developed embryonal rhabdomyosarcomas expressing desmin, myosin, and insulin-like growth factor-II, in the genitourinary tract. Our findings led to the hypothesis that the interaction between HER family genes and the p53 pathway might be involved in the origin of human rhabdomyosarcoma.
引用
收藏
页码:2728 / 2732
页数:5
相关论文
共 50 条
  • [21] Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan
    Tsai, YS
    Tzai, TS
    Chow, NH
    Yang, WH
    Tong, YC
    Lin, JSN
    Chang, CC
    Cheng, HL
    Lin, YM
    UROLOGIA INTERNATIONALIS, 2003, 71 (03) : 262 - 270
  • [22] P53 AND HER-2/NEU ARE RARELY IMMUNOHISTOCHEMICALLY DETECTABLE IN MALE BREAST-CANCER
    MIES, C
    MEJIAS, A
    NADJI, M
    MORALES, A
    LABORATORY INVESTIGATION, 1994, 70 (01) : A19 - A19
  • [23] Immunohistochemical Evaluation of Androgen Receptor, HER-2/neu, and p53 in Benign Pleomorphic Adenomas
    DeRoche, Tom C.
    Hoschar, Aaron P.
    Hunt, Jennifer L.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2008, 132 (12) : 1907 - 1911
  • [24] Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer
    Nijman, HW
    Kenemans, P
    Poort-Keesom, RJJ
    Verstraeten, RA
    Mensdorff-Pouilly, S
    Verheijen, RHM
    Melief, CJM
    Hilgers, J
    Meijer, CJLM
    EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1999, 83 (02): : 201 - 206
  • [25] High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.
    Sawaki M.
    Ito Y.
    Akiyama F.
    Tokudome N.
    Horii R.
    Mizunuma N.
    Takahashi S.
    Horikoshi N.
    Imai T.
    Nakao A.
    Kasumi F.
    Sakamoto G.
    Hatake K.
    Breast Cancer, 2006, 13 (2) : 172 - 178
  • [26] Her-2/neu, bcl-2 and p53 expression in neuroendocrine tumors of the pancreas.
    Proca, DM
    DeYoung, BR
    Frankel, WL
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 114 (04) : 639 - 639
  • [27] Aromatase, Cyclooxygenase 2, HER-2/neu, and P53 as Prognostic Factors in Endometrioid Endometrial Cancer
    Jongen, Vincent H. W. M.
    Briet, Justine M.
    de Jong, Renske A.
    Joppe, Erna
    ten Hoor, Klaske A.
    Boezen, H. M.
    Evans, Dean B.
    Hollema, Harry
    van der Zee, Ate G. J.
    Nijman, Hans W.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (04) : 670 - 676
  • [28] Epithalon decelerates aging and suppresses development of breast, adenocarcinomas in transgenic HER-2/neu mice
    Anisimov, VN
    Khavinson, VK
    Alimova, IN
    Semchenko, AV
    Yashin, AI
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2002, 134 (02) : 187 - 190
  • [29] The effect of melatonin treatment regimen on mammary adenocarcinoma development in HER-2/neu transgenic mice
    Anisimov, VN
    Alimova, IN
    Baturin, DA
    Popovich, IG
    Zabezhinski, MA
    Manton, KG
    Semenchenko, AV
    Yashin, A
    INTERNATIONAL JOURNAL OF CANCER, 2003, 103 (03) : 300 - 305
  • [30] Epithalon Decelerates Aging and Suppresses Development of Breast Adenocarcinomas in Transgenic HER-2/neu Mice
    V. N. Anisimov
    V. Kh. Khavinson
    I. N. Alimova
    A. V. Semchenko
    A. I. Yashin
    Bulletin of Experimental Biology and Medicine, 2002, 134 : 187 - 190